Abstract
4-Aminoquinazoline analogs have been identified as a new class of cancer chemotherapeutic agents with significant therapeutic efficacy against solid tumors. They are potent and highly selective inhibitors of tyrosine kinase (TK) and epidermal growth factor receptor (EGFR). Till date various 4-aminoquinazoline analogs have been synthesized and evaluated for anticancer activity. This review is an attempt to compile the medicinal chemistry of various synthesized 4-aminoquinazoline analogs.
Keywords: 4-Aminoquinazoline, antitumor, apoptosis, cytotoxic, epidermal growth factor receptor, tyrosine kinase.
Mini-Reviews in Medicinal Chemistry
Title:4-Aminoquinazoline Analogs: A Novel Class of Anticancer Agents
Volume: 13 Issue: 8
Author(s): Kalpana Singh, P.P. Sharma, A. Kumar, Anurag Chaudhary and R.K. Roy
Affiliation:
Keywords: 4-Aminoquinazoline, antitumor, apoptosis, cytotoxic, epidermal growth factor receptor, tyrosine kinase.
Abstract: 4-Aminoquinazoline analogs have been identified as a new class of cancer chemotherapeutic agents with significant therapeutic efficacy against solid tumors. They are potent and highly selective inhibitors of tyrosine kinase (TK) and epidermal growth factor receptor (EGFR). Till date various 4-aminoquinazoline analogs have been synthesized and evaluated for anticancer activity. This review is an attempt to compile the medicinal chemistry of various synthesized 4-aminoquinazoline analogs.
Export Options
About this article
Cite this article as:
Singh Kalpana, Sharma P.P., Kumar A., Chaudhary Anurag and Roy R.K., 4-Aminoquinazoline Analogs: A Novel Class of Anticancer Agents, Mini-Reviews in Medicinal Chemistry 2013; 13 (8) . https://dx.doi.org/10.2174/1389557511313080006
DOI https://dx.doi.org/10.2174/1389557511313080006 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Clinical Advances in Immuno-oncology – Progress Towards Selective Cure)
Current Molecular Pharmacology The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry Estrogen Regulation of MicroRNA Expression
Current Genomics Patent Selections
Recent Patents on Biomarkers Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Lung Cancer Classification and Gene Selection by Combining Affinity Propagation Clustering and Sparse Group Lasso
Current Bioinformatics The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Laccases in Pharmaceutical Chemistry: A Comprehensive Appraisal
Mini-Reviews in Organic Chemistry Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy
Current Radiopharmaceuticals MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Anti-Cancer Potential of a Novel SERM Ormeloxifene
Current Medicinal Chemistry